vs
安捷伦科技（A）与通用电气医疗（GEHC）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是安捷伦科技的3.2倍（$5.7B vs $1.8B）。安捷伦科技净利率更高（17.0% vs 10.3%，领先6.6%）。通用电气医疗同比增速更快（7.1% vs 7.0%）。过去两年通用电气医疗的营收复合增速更高（10.7% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、核磁共振、女性健康筛查、X射线系统）、超声、患者护理解决方案（聚焦远程患者监测、麻醉呼吸护理、心脏病诊断、婴幼儿照护）及制药诊断业务。
A vs GEHC — 直观对比
营收规模更大
GEHC
是对方的3.2倍
$1.8B
营收增速更快
GEHC
高出0.1%
7.0%
净利率更高
A
高出6.6%
10.3%
两年增速更快
GEHC
近两年复合增速
6.9%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $5.7B |
| 净利润 | $305.0M | $588.0M |
| 毛利率 | 52.6% | 39.7% |
| 营业利润率 | 19.6% | 14.5% |
| 净利率 | 17.0% | 10.3% |
| 营收同比 | 7.0% | 7.1% |
| 净利润同比 | -4.1% | -18.4% |
| 每股收益（稀释后） | $1.07 | $1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGEHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $5.7B | ||
| Q3 25 | $1.7B | $5.1B | ||
| Q2 25 | $1.7B | $5.0B | ||
| Q1 25 | $1.7B | $4.8B | ||
| Q4 24 | $1.7B | $5.3B | ||
| Q3 24 | $1.6B | $4.9B | ||
| Q2 24 | $1.6B | $4.8B |
净利润AGEHC
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $588.0M | ||
| Q3 25 | $336.0M | $446.0M | ||
| Q2 25 | $215.0M | $486.0M | ||
| Q1 25 | $318.0M | $564.0M | ||
| Q4 24 | $351.0M | $721.0M | ||
| Q3 24 | $282.0M | $470.0M | ||
| Q2 24 | $308.0M | $428.0M |
毛利率AGEHC
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 39.7% | ||
| Q3 25 | 51.1% | 38.7% | ||
| Q2 25 | 51.9% | 39.6% | ||
| Q1 25 | 53.5% | 42.1% | ||
| Q4 24 | 53.9% | 42.8% | ||
| Q3 24 | 54.2% | 41.7% | ||
| Q2 24 | 54.4% | 41.4% |
营业利润率AGEHC
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 14.5% | ||
| Q3 25 | 20.7% | 12.7% | ||
| Q2 25 | 18.0% | 13.1% | ||
| Q1 25 | 22.4% | 13.2% | ||
| Q4 24 | 24.0% | 15.1% | ||
| Q3 24 | 21.1% | 13.9% | ||
| Q2 24 | 23.1% | 12.6% |
净利率AGEHC
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 10.3% | ||
| Q3 25 | 19.3% | 8.7% | ||
| Q2 25 | 12.9% | 9.7% | ||
| Q1 25 | 18.9% | 11.8% | ||
| Q4 24 | 20.6% | 13.6% | ||
| Q3 24 | 17.9% | 9.7% | ||
| Q2 24 | 19.6% | 8.8% |
每股收益（稀释后）AGEHC
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $1.28 | ||
| Q3 25 | $1.18 | $0.98 | ||
| Q2 25 | $0.75 | $1.06 | ||
| Q1 25 | $1.11 | $1.23 | ||
| Q4 24 | $1.23 | $1.58 | ||
| Q3 24 | $0.97 | $1.02 | ||
| Q2 24 | $1.05 | $0.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $4.5B |
| 总债务越低越好 | $3.0B | $10.0B |
| 股东权益账面价值 | $6.9B | $10.4B |
| 总资产 | $12.8B | $36.9B |
| 负债/权益比越低杠杆越低 | 0.44× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资AGEHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $4.5B | ||
| Q3 25 | $1.5B | $4.0B | ||
| Q2 25 | $1.5B | $3.7B | ||
| Q1 25 | $1.5B | $2.5B | ||
| Q4 24 | $1.3B | $2.9B | ||
| Q3 24 | $1.8B | $3.5B | ||
| Q2 24 | $1.7B | $2.0B |
总债务AGEHC
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $10.0B | ||
| Q3 25 | $3.4B | $10.3B | ||
| Q2 25 | $3.3B | $10.3B | ||
| Q1 25 | $3.3B | $8.8B | ||
| Q4 24 | $3.3B | $9.0B | ||
| Q3 24 | $2.1B | $10.3B | ||
| Q2 24 | $2.1B | $9.2B |
股东权益AGEHC
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $10.4B | ||
| Q3 25 | $6.4B | $10.0B | ||
| Q2 25 | $6.1B | $9.7B | ||
| Q1 25 | $6.0B | $9.2B | ||
| Q4 24 | $5.9B | $8.4B | ||
| Q3 24 | $5.9B | $8.3B | ||
| Q2 24 | $6.2B | $7.8B |
总资产AGEHC
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $36.9B | ||
| Q3 25 | $12.2B | $36.1B | ||
| Q2 25 | $12.2B | $35.5B | ||
| Q1 25 | $11.9B | $33.6B | ||
| Q4 24 | $11.8B | $33.1B | ||
| Q3 24 | $11.0B | $33.9B | ||
| Q2 24 | $10.9B | $31.9B |
负债/权益比AGEHC
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.96× | ||
| Q3 25 | 0.53× | 1.03× | ||
| Q2 25 | 0.55× | 1.06× | ||
| Q1 25 | 0.56× | 0.95× | ||
| Q4 24 | 0.57× | 1.06× | ||
| Q3 24 | 0.36× | 1.24× | ||
| Q2 24 | 0.34× | 1.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | — |
| 自由现金流经营现金流 - 资本支出 | $175.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 5.2% | 2.4% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | — |
8季度趋势，按日历期对齐
经营现金流AGEHC
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $362.0M | — | ||
| Q2 25 | $221.0M | $94.0M | ||
| Q1 25 | $431.0M | $250.0M | ||
| Q4 24 | $481.0M | — | ||
| Q3 24 | $452.0M | — | ||
| Q2 24 | $333.0M | $-119.0M |
自由现金流AGEHC
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | — | ||
| Q3 25 | $259.0M | — | ||
| Q2 25 | $107.0M | $8.0M | ||
| Q1 25 | $334.0M | $98.0M | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | $-183.0M |
自由现金流率AGEHC
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 6.4% | 0.2% | ||
| Q1 25 | 19.9% | 2.1% | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | -3.8% |
资本支出强度AGEHC
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 2.4% | ||
| Q3 25 | 5.9% | 2.1% | ||
| Q2 25 | 6.8% | 1.7% | ||
| Q1 25 | 5.8% | 3.2% | ||
| Q4 24 | 5.5% | 1.9% | ||
| Q3 24 | 5.8% | 1.9% | ||
| Q2 24 | 6.5% | 1.3% |
现金转化率AGEHC
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | 0.19× | ||
| Q1 25 | 1.36× | 0.44× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
